Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Universal Donor Cancer Immunotherapy To Be Developed By Regen Biopharma

XTALKS VITALS NEWS

Blood

As part of a provisional patent application, the company plans to create cord blood-derived killer cells, which will be paired with gene silencing techniques to target and destroy cancer cells.

Share this!

May 24, 2016 | by Sarah Massey, M.Sc.

Early-stage biotech company, Regen BioPharma, has started preclinical development on the first cancer immunotherapy using cells extracted from cord blood. The San Diego-based company will focus on developing a therapy targeting the NR2F6 immunological checkpoint.

As part of a provisional patent application, the company plans to create cord blood-derived killer cells, which will be paired with gene silencing techniques to target and destroy cancer cells. The potential benefit of this product – known as ucVax – is that the platform will act as a universal donor for cellular immunotherapy. This means that the cells could be frozen and delivered to site of use, without requiring the hospital or treatment center to perform any complicated cellular engineering.

“Developing a universal donor immunotherapy will substantially reduce costs of clinical implementation and allow for wide access to treatment including at institutions that do not possess cellular processing abilities,” said David Koos, chairman and CEO of Regen BioPharma. “To our knowledge, universal donor cellular immunotherapies have not been developed to date. We believe ucVax will possess both therapeutic and commercial advantages as compared to other immunotherapies.”



Current cancer immunotherapy processes are labor-intensive, involving extraction, manipulation and subsequent re-infusion of a patient’s blood cells. While it has proved to be a promising new tool in cancer treatment, it’s also a costly form of personalized medicine.

Regen BioPharma’s ucVax product is, admittedly, in the very early stages of development, and much more research and development must be performed before the product could ever be used in a clinical setting. What’s more, the company says they’re only planning to develop the product from preclinical to midstage testing, which suggests they’ll be looking for future partners capable of getting the technology to market.

“By using cord blood cells as the starting population for generation of ucVax, we overcome the problem of immune rejection by the patient receiving the therapy, thus potentially allowing the therapy to be used by everyone in need,” said Harry Lander, president and CSO of Regen BioPharma. The biotech’s overall focus is in the regenerative medicine space, with other immunotherapy and stem cell treatments currently in development.


Keywords: Immunotherapy, Cancer, Biotech


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.